The Food and Drug Administration granted accelerated approval to tarlatamab-dlle, or Imdelltra, from Amgen for extensive stage small cell lung cancer, or ES-SCLC, with disease progression on or after platinum-based chemotherapy.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMGN:
- Dow Jones (DJIA) Dominates in May: Here’s Why the Trend Could Continue
- Amgen price target raised to $235 from $223 at Mizuho
- Wedbush upgrades CytomX to Outperform on ‘encouraging’ CX-904 Phase 1a data
- Drugmakers work to make treatments to maintain weight loss, WSJ reports
- Fly Insider: Theravance Bio, Amgen among week’s notable insider trades